Premium
Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis
Author(s) -
Ozorio Gerard,
McGarity Bruce,
Bak Haesung,
Jordan Andrew S,
Lau Henry,
Marshall Cathy
Publication year - 2007
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2007.tb01396.x
Subject(s) - medicine , ankylosing spondylitis , general hospital , general surgery , family medicine , surgery
Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-alpha (TNF-alpha) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-alpha agents, and periodic monitoring for the development of hepatitis is important.